Market Research Logo

Cancer Biological Therapy Market Size By Product (Monoclonal Antibodies {Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies}, Vaccines {Preventive Vaccines, Therapeutic Vaccines}, Cancer Growth Blockers {Tyrosi

Cancer Biological Therapy Market Size By Product (Monoclonal Antibodies {Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies}, Vaccines {Preventive Vaccines, Therapeutic Vaccines}, Cancer Growth Blockers {Tyrosine Kinase Inhibitors, Proteasome Inhibitors, mTOR Inhibitors}, Blood Cell Growth Factors {Lenograstim, Filgrastim}, Cytokine {Interferon, Interleukin}), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, India, China, Japan, Brazil, Argentina, Mexico, South Africa, Saudi Arabia, UAE), Application Potential, Competitive Market Share & Forecast, 2018 - 2024

Cancer Biological Therapy Market will exceed USD 108 billion by 2024; as per a new research report.

Growing geriatric population will drive cancer biological therapy industry growth during forecast timeframe. Elderly population in the age group of 50 years and above is more susceptible to cancer that escalates demand for cancer biologic therapies. Cancer biological therapy is utilized to boost immune system and has commendable specificity that helps in faster recovery. High preference for cancer biological therapy for treating geriatric population suffering from cancer will positively influence industry growth over forthcoming years.

Increasing R&D funding by government in various pharmaceutical, biopharmaceutical companies as well as research institutes involved in developing cancer drugs will foster cancer biologics market growth. Funds raised by governments in developed countries such as UK have facilitated cancer drug discovery process and has also enhanced operational capabilities of the companies and research centers involved in developing cancer biological therapy drugs and vaccines. Moreover, favorable government policies and regulatory framework facilitating drug discovery process will substantially augment cancer biologics industry growth. However, adverse effects of anti-cancer drug therapy may lower its preference and hamper business growth up to some extent.

Vaccines segment was valued at USD 2.0 billion in 2017 and is expected to have considerable revenue size over forthcoming years. Vaccines utilized in cancer treatment possess high efficiency and have ability to increase immunity by recognizing and destroying specific antigens. Moreover, vaccines also create immunogenic response that reduces risk of acquiring cancer again in future and are most effective in treatment of bladder, breast and cervical cancer. Aforementioned factors coupled with growing incidences of breast cancer in developing economies such as India will stimulate segmental growth.

India cancer biological therapy market accounted for 18.3% revenue share in 2017 and is anticipated to have exponential growth during forecast timeframe. According to WHO, cancer is one of major causes of mortality and morbidity in India. Furthermore, availability of efficient cancer biological therapy has considerably increased survival rate in cancer patients. Aforementioned factors along with growing awareness regarding cancer treatment amongst people residing in rural India will trigger Indian cancer biological therapy industry growth during analysis period.

Germany cancer biological therapy market was valued at USD 4.0 billion in 2017. Increasing prevalence of cancer in Germany will surge demand for cancer biologics therapy. High prevalence of cancer will propel demand for cancer biologics thereby, enhancing Germany cancer biologics industry growth.

Some of the eminent industry players operating in cancer biological therapy industry includes AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals and Takeda Pharmaceuticals. Key industry players implement several strategies such as mergers, acquisition, geographic expansions and new product launch that enables them to achieve sustainable profits. Receiving FDA approvals for newly developed drugs will also foster company’s revenue generation. For instance, in November 2018, Roche and Abbvie received FDA approval for Venclexta, a BCL-2 inhibitor effective in the treatment of leukemia. Venclexta is jointly commercialized by Abbvie and Genetech, a part of Roche Group in the U.S. and is sold solely by Abbvie outside of the U.S. Receiving approvals for new drugs will boost Abbvie’s as well as Roche’s profits.


Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Cancer biological therapy industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. Cancer Biological Therapy Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing incidence of cancer worldwide
3.3.1.2. Growing geriatric population
3.3.1.3. Technological advancement in cancer biologics in developed countries
3.3.1.4. Increasing R&D funding coupled with favorable government policies
3.3.2. Industry pitfalls and challenges
3.3.2.1. High cost of treatment
3.3.2.2. Adverse effects of anti-cancer drug therapy
3.4. Growth potential analysis
3.4.1. By product
3.5. Porter's analysis
3.6. Competitive landscape, 2017
3.6.1. Strategy dashboard
3.7. PESTEL analysis
Chapter 4. Cancer Biological Therapy Market, By Product
4.1. Key segment trends
4.2. Monoclonal antibodies (MAB)
4.2.1. Market size, by region, 2013 - 2024
4.2.2. Naked MAB
4.2.2.1. Market size, by region, 2013 - 2024
4.2.3. Conjugated MAB
4.2.3.1. Market size, by region, 2013 - 2024
4.2.4. Bispecific MAB
4.2.4.1. Market size, by region, 2013 - 2024
4.3. Vaccines
4.3.1. Market size, by region, 2013 - 2024
4.3.2. Preventive vaccines
4.3.2.1. Market size, by region, 2013 - 2024
4.3.3. Therapeutic vaccines
4.3.3.1. Market size, by region, 2013 - 2024
4.4. Cancer growth blockers
4.4.1. Market size, by region, 2013 - 2024
4.4.2. Tyrosine kinase Inhibitors (TKI)
4.4.2.1. Market size, by region, 2013 - 2024
4.4.3. Proteasome Inhibitors (PI)
4.4.3.1. Market size, by region, 2013 - 2024
4.4.4. mTOR Inhibitors
4.4.4.1. Market size, by region, 2013 - 2024
4.5. Blood cell growth factors (BCGF)
4.5.1. Market size, by region, 2013 - 2024
4.5.2. Lenograstim
4.5.2.1. Market size, by region, 2013 - 2024
4.5.3. Filgrastim
4.5.3.1. Market size, by region, 2013 - 2024
4.6. Cytokines
4.6.1. Market size, by region, 2013 - 2024
4.6.2. Interferons
4.6.2.1. Market size, by region, 2013 - 2024
4.6.3. Interleukins
4.6.3.1. Market size, by region, 2013 - 2024
Chapter 5. Cancer Biological Therapy Market, By Region
5.1. Key regional trends
5.2. North America
5.2.1. Market size, by country 2013 - 2024
5.2.2. Market size, by product, 2013 - 2024
5.2.2.1. Market size, by MAB, 2013 - 2024
5.2.2.2. Market size, by vaccines, 2013 - 2024
5.2.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.2.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.2.2.5. Market size, by cytokines, 2013 - 2024
5.2.3. U.S.
5.2.3.1. Market size, by product, 2013 - 2024
5.2.3.1.1. Market size, by MAB, 2013 - 2024
5.2.3.1.2. Market size, by vaccines, 2013 - 2024
5.2.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.2.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.2.3.1.5. Market size, by cytokines, 2013 - 2024
5.2.4. Canada
5.2.4.1. Market size, by product, 2013 - 2024
5.2.4.1.1. Market size, by MAB, 2013 - 2024
5.2.4.1.2. Market size, by vaccines, 2013 - 2024
5.2.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.2.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.2.4.1.5. Market size, by cytokines, 2013 - 2024
5.3. Europe
5.3.1. Market size, by country 2013 - 2024
5.3.2. Market size, by product, 2013 - 2024
5.3.2.1. Market size, by MAB, 2013 - 2024
5.3.2.2. Market size, by vaccines, 2013 - 2024
5.3.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.2.5. Market size, by cytokines, 2013 - 2024
5.3.3. Germany
5.3.3.1. Market size, by product, 2013 - 2024
5.3.3.1.1. Market size, by MAB, 2013 - 2024
5.3.3.1.2. Market size, by vaccines, 2013 - 2024
5.3.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.3.1.5. Market size, by cytokines, 2013 - 2024
5.3.4. UK
5.3.4.1. Market size, by product, 2013 - 2024
5.3.4.1.1. Market size, by MAB, 2013 - 2024
5.3.4.1.2. Market size, by vaccines, 2013 - 2024
5.3.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.4.1.5. Market size, by cytokines, 2013 - 2024
5.3.5. France
5.3.5.1. Market size, by product, 2013 - 2024
5.3.5.1.1. Market size, by MAB, 2013 - 2024
5.3.5.1.2. Market size, by vaccines, 2013 - 2024
5.3.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.5.1.5. Market size, by cytokines, 2013 - 2024
5.3.6. Spain
5.3.6.1. Market size, by product, 2013 - 2024
5.3.6.1.1. Market size, by MAB, 2013 - 2024
5.3.6.1.2. Market size, by vaccines, 2013 - 2024
5.3.6.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.6.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.6.1.5. Market size, by cytokines, 2013 - 2024
5.3.7. Italy
5.3.7.1. Market size, by product, 2013 - 2024
5.3.7.1.1. Market size, by MAB, 2013 - 2024
5.3.7.1.2. Market size, by vaccines, 2013 - 2024
5.3.7.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.3.7.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.3.7.1.5. Market size, by cytokines, 2013 - 2024
5.4. Asia Pacific
5.4.1. Market size, by country 2013 - 2024
5.4.2. Market size, by product, 2013 - 2024
5.4.2.1. Market size, by MAB, 2013 - 2024
5.4.2.2. Market size, by vaccines, 2013 - 2024
5.4.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.2.5. Market size, by cytokines, 2013 - 2024
5.4.3. India
5.4.3.1. Market size, by product, 2013 - 2024
5.4.3.1.1. Market size, by MAB, 2013 - 2024
5.4.3.1.2. Market size, by vaccines, 2013 - 2024
5.4.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.3.1.5. Market size, by cytokines, 2013 - 2024
5.4.4. China
5.4.4.1. Market size, by product, 2013 - 2024
5.4.4.1.1. Market size, by MAB, 2013 - 2024
5.4.4.1.2. Market size, by vaccines, 2013 - 2024
5.4.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.4.1.5. Market size, by cytokines, 2013 - 2024
5.4.5. Japan
5.4.5.1. Market size, by product, 2013 - 2024
5.4.5.1.1. Market size, by MAB, 2013 - 2024
5.4.5.1.2. Market size, by vaccines, 2013 - 2024
5.4.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.4.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.4.5.1.5. Market size, by cytokines, 2013 - 2024
5.5. Latin America
5.5.1. Market size, by country 2013 - 2024
5.5.2. Market size, by product, 2013 - 2024
5.5.2.1. Market size, by MAB, 2013 - 2024
5.5.2.2. Market size, by vaccines, 2013 - 2024
5.5.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.2.5. Market size, by cytokines, 2013 - 2024
5.5.3. Brazil
5.5.3.1. Market size, by product, 2013 - 2024
5.5.3.1.1. Market size, by MAB, 2013 - 2024
5.5.3.1.2. Market size, by vaccines, 2013 - 2024
5.5.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.3.1.5. Market size, by cytokines, 2013 - 2024
5.5.4. Argentina
5.5.4.1. Market size, by product, 2013 - 2024
5.5.4.1.1. Market size, by MAB, 2013 - 2024
5.5.4.1.2. Market size, by vaccines, 2013 - 2024
5.5.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.4.1.5. Market size, by cytokines, 2013 - 2024
5.5.5. Mexico
5.5.5.1. Market size, by product, 2013 - 2024
5.5.5.1.1. Market size, by MAB, 2013 - 2024
5.5.5.1.2. Market size, by vaccines, 2013 - 2024
5.5.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.5.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.5.5.1.5. Market size, by cytokines, 2013 - 2024
5.6. MEA
5.6.1. Market size, by country 2013 - 2024
5.6.2. Market size, by product, 2013 - 2024
5.6.2.1. Market size, by MAB, 2013 - 2024
5.6.2.2. Market size, by vaccines, 2013 - 2024
5.6.2.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.2.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.2.5. Market size, by cytokines, 2013 - 2024
5.6.3. South Africa
5.6.3.1. Market size, by product, 2013 - 2024
5.6.3.1.1. Market size, by MAB, 2013 - 2024
5.6.3.1.2. Market size, by vaccines, 2013 - 2024
5.6.3.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.3.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.3.1.5. Market size, by cytokines, 2013 - 2024
5.6.4. Saudi Arabia
5.6.4.1. Market size, by product, 2013 - 2024
5.6.4.1.1. Market size, by MAB, 2013 - 2024
5.6.4.1.2. Market size, by vaccines, 2013 - 2024
5.6.4.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.4.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.4.1.5. Market size, by cytokines, 2013 - 2024
5.6.5. UAE
5.6.5.1. Market size, by product, 2013 - 2024
5.6.5.1.1. Market size, by MAB, 2013 - 2024
5.6.5.1.2. Market size, by vaccines, 2013 - 2024
5.6.5.1.3. Market size, by cancer growth blockers, 2013 - 2024
5.6.5.1.4. Market size, by blood cell growth factors, 2013 - 2024
5.6.5.1.5. Market size, by cytokines, 2013 - 2024
Chapter 6. Company Profiles
6.1. AbbVie
6.1.1. Business overview
6.1.2. Financial data
6.1.3. Product landscape
6.1.4. Strategic outlook
6.1.5. SWOT analysis
6.2. Amgen
6.2.1. Business overview
6.2.2. Financial data
6.2.3. Product landscape
6.2.4. Strategic outlook
6.2.5. SWOT analysis
6.3. Astellas
6.3.1. Business overview
6.3.2. Financial data
6.3.3. Product landscape
6.3.4. Strategic outlook
6.3.5. SWOT analysis
6.4. AstraZeneca
6.4.1. Business overview
6.4.2. Financial data
6.4.3. Product landscape
6.4.4. Strategic outlook
6.4.5. SWOT analysis
6.5. Bayer
6.5.1. Business overview
6.5.2. Financial data
6.5.3. Product landscape
6.5.4. Strategic outlook
6.5.5. SWOT analysis
6.6. Celgene Corporation
6.6.1. Business overview
6.6.2. Financial data
6.6.3. Product landscape
6.6.4. Strategic outlook
6.6.5. SWOT analysis
6.7. Eisai
6.7.1. Business overview
6.7.2. Financial data
6.7.3. Product landscape
6.7.4. Strategic outlook
6.7.5. SWOT analysis
6.8. ELI Lilly and Company
6.8.1. Business overview
6.8.2. Financial data
6.8.3. Product landscape
6.8.4. Strategic outlook
6.8.5. SWOT analysis
6.9. F. Hoffmann-La Roche
6.9.1. Business overview
6.9.2. Financial data
6.9.3. Product landscape
6.9.4. Strategic outlook
6.9.5. SWOT analysis
6.10. GlaxoSmithKline
6.10.1. Business overview
6.10.2. Financial data
6.10.3. Product landscape
6.10.4. Strategic outlook
6.10.5. SWOT analysis
6.11. Incyte
6.11.1. Business overview
6.11.2. Financial data
6.11.3. Product landscape
6.11.4. Strategic outlook
6.11.5. SWOT analysis
6.12. Merck
6.12.1. Business overview
6.12.2. Financial data
6.12.3. Product landscape
6.12.4. Strategic outlook
6.12.5. SWOT analysis
6.13. Novartis
6.13.1. Business overview
6.13.2. Financial data
6.13.3. Product landscape
6.13.4. Strategic outlook
6.13.5. SWOT analysis
6.14. Otsuka
6.14.1. Business overview
6.14.2. Financial data
6.14.3. Product landscape
6.14.4. Strategic outlook
6.14.5. SWOT analysis
6.15. Pfizer
6.15.1. Business overview
6.15.2. Financial data
6.15.3. Product landscape
6.15.4. Strategic outlook
6.15.5. SWOT analysis
6.16. Sanofi
6.16.1. Business overview
6.16.2. Financial data
6.16.3. Product landscape
6.16.4. Strategic outlook
6.16.5. SWOT analysis
6.17. Seattle Genetics
6.17.1. Business overview
6.17.2. Financial data
6.17.3. Product landscape
6.17.4. Strategic outlook
6.17.5. SWOT analysis
6.18. Spectrum Pharmaceuticals
6.18.1. Business overview
6.18.2. Financial data
6.18.3. Product landscape
6.18.4. Strategic outlook
6.18.5. SWOT analysis
6.19. Takeda Pharmaceuticals
6.19.1. Business overview
6.19.2. Financial data
6.19.3. Product landscape
6.19.4. Strategic outlook
6.19.5. SWOT analysis
Data Tables/B>
TABLE 1 Cancer biological therapy (CBT) industry 360º synopsis, 2013 - 2024
TABLE 2 Cancer biological therapy market, 2013-2017 (USD Million)
TABLE 3 Cancer biological therapy market, 2018-2024 (USD Million)
TABLE 4 Cancer biological therapy market, by product, 2013-2017 (USD Million)
TABLE 5 Cancer biological therapy market, by product, 2018-2024 (USD Million)
TABLE 6 Cancer biological therapy market, by region, 2013-2017 (USD Million)
TABLE 7 Cancer biological therapy market, by region, 2018-2024 (USD Million)
TABLE 8 Industry impact forces
TABLE 9 Monoclonal antibodies market size, by region, 2013-2017 (USD Million)
TABLE 10 Monoclonal antibodies market size, by region, 2018-2024 (USD Million)
TABLE 11 Naked MAB market size, by region, 2013-2017 (USD Million)
TABLE 12 Naked MAB market size, by region, 2018-2024 (USD Million)
TABLE 13 Conjugated MAB market size, by region, 2013-2017 (USD Million)
TABLE 14 Conjugated MAB market size, by region, 2018-2024 (USD Million)
TABLE 15 Bi specific MAB market size, by region, 2013-2017 (USD Million)
TABLE 16 Bi specific MAB market size, by region, 2018-2024 (USD Million)
TABLE 17 Vaccines market size, by region, 2013-2017 (USD Million)
TABLE 18 Vaccines market size, by region, 2018-2024 (USD Million)
TABLE 19 Preventive vaccines market size, by region, 2013-2017 (USD Million)
TABLE 20 Preventive vaccines market size, by region, 2018-2024 (USD Million)
TABLE 21 Therapeutic vaccines market size, by region, 2013-2017 (USD Million)
TABLE 22 Therapeutic vaccines market size, by region, 2018-2024 (USD Million)
TABLE 23 Cancer growth blockers market size, by region, 2013-2017 (USD Million)
TABLE 24 Cancer growth blockers market size, by region, 2018-2024 (USD Million)
TABLE 25 TKI market size, by region, 2013-2017 (USD Million)
TABLE 26 TKI market size, by region, 2018-2024 (USD Million)
TABLE 27 PI market size, by region, 2013-2017 (USD Million)
TABLE 28 PI market size, by region, 2018-2024 (USD Million)
TABLE 29 mTOR Inhibitors market size, by region, 2013-2017 (USD Million)
TABLE 30 mTOR Inhibitors market size, by region, 2018-2024 (USD Million)
TABLE 31 BCGF market size, by region, 2013-2017 (USD Million)
TABLE 32 BCGF market size, by region, 2018-2024 (USD Million)
TABLE 33 Lenograstim market size, by region, 2013-2017 (USD Million)
TABLE 34 Lenograstim market size, by region, 2018-2024 (USD Million)
TABLE 35 Filgrastim market size, by region, 2013-2017 (USD Million)
TABLE 36 Filgrastim market size, by region, 2018-2024 (USD Million)
TABLE 37 Cytokines market size, by region, 2013-2017 (USD Million)
TABLE 38 Cytokines market size, by region, 2018-2024 (USD Million)
TABLE 39 Interferons market size, by region, 2013-2017 (USD Million)
TABLE 40 Interferons market size, by region, 2018-2024 (USD Million)
TABLE 41 Interleukins market size, by region, 2013-2017 (USD Million)
TABLE 42 Interleukins market size, by region, 2018-2024 (USD Million)
TABLE 43 North America cancer biological therapy market size, by country, 2013-2017 (USD Million)
TABLE 44 North America cancer biological therapy market size, by country, 2018-2024 (USD Million)
TABLE 45 North America CBT market size, by product, 2013-2017 (USD Million)
TABLE 46 North America CBT market size, by product, 2018-2024 (USD Million)
TABLE 47 North America CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 48 North America CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 49 North America CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 50 North America CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 51 North America CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 52 North America CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 53 North America CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 54 North America CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 55 North America CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 56 North America CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 57 U.S. cancer biological therapy market size, by product, 2013-2017 (USD Million)
TABLE 58 U.S. cancer biological therapy market size, by product, 2018-2024 (USD Million)
TABLE 59 U.S. CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 60 U.S. CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 61 U.S. CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 62 U.S. CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 63 U.S. CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 64 U.S. CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 65 U.S. CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 66 U.S. CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 67 U.S. CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 68 U.S. CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 69 Canada CBT market size, by product, 2013-2017 (USD Million)
TABLE 70 Canada CBT market size, by product, 2018-2024 (USD Million)
TABLE 71 Canada CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 72 Canada CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 73 Canada CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 74 Canada CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 75 Canada CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 76 Canada CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 77 Canada CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 78 Canada CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 79 Canada CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 80 Canada CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 81 Europe CBT size, by country, 2013-2017 (USD Million)
TABLE 82 Europe CBT size, by country, 2018-2024 (USD Million)
TABLE 83 Europe CBT size, by product, 2013-2017 (USD Million)
TABLE 84 Europe CBT size, by product, 2018-2024 (USD Million)
TABLE 85 Europe CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 86 Europe CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 87 Europe CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 88 Europe CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 89 Europe CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 90 Europe CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 91 Europe CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 92 Europe CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 93 Europe CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 94 Europe CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 95 Germany CBT market size, by product, 2013-2017 (USD Million)
TABLE 96 Germany CBT market size, by product, 2018-2024 (USD Million)
TABLE 97 Germany CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 98 Germany CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 99 Germany CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 100 Germany CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 101 Germany CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 102 Germany CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 103 Germany CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 104 Germany CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 105 Germany CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 106 Germany CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 107 UK CBT market size, by product, 2013-2017 (USD Million)
TABLE 108 UK CBT market size, by product, 2018-2024 (USD Million)
TABLE 109 UK CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 110 UK CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 111 UK CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 112 UK CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 113 UK CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 114 UK CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 115 UK CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 116 UK CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 117 UK CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 118 UK CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 119 France CBT market size, by product, 2013-2017 (USD Million)
TABLE 120 France CBT market size, by product, 2018-2024 (USD Million)
TABLE 121 France CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 122 France CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 123 France CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 124 France CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 125 France CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 126 France CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 127 France CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 128 France CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 129 France CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 130 France CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 131 Spain market CBT size, by product, 2013-2017 (USD Million)
TABLE 132 Spain CBT market size, by product, 2018-2024 (USD Million)
TABLE 133 Spain CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 134 Spain CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 135 Spain CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 136 Spain CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 137 Spain CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 138 Spain CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 139 Spain CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 140 Spain CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 141 Spain CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 142 Spain CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 143 Italy CBT market size, by product, 2013-2017 (USD Million)
TABLE 144 Italy CBT market size, by product, 2018-2024 (USD Million)
TABLE 145 Italy CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 146 Italy CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 147 Italy CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 148 Italy CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 149 Italy CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 150 Italy CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 151 Italy CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 152 Italy CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 153 Italy CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 154 Italy CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 155 Asia Pacific CBT market size, by country, 2013-2017 (USD Million)
TABLE 156 Asia Pacific CBT market size, by country, 2018-2024 (USD Million)
TABLE 157 Asia Pacific CBT market size, by product, 2013-2017 (USD Million)
TABLE 158 Asia Pacific CBT market size, by product, 2018-2024 (USD Million)
TABLE 159 Asia Pacific CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 160 Asia Pacific CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 161 Asia Pacific CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 162 Asia Pacific CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 163 Asia Pacific CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 164 Asia Pacific CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 165 Asia Pacific CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 166 Asia Pacific CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 167 Asia Pacific CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 168 Asia Pacific CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 169 India CBT market size, by product, 2013-2017 (USD Million)
TABLE 170 India CBT market size, by product, 2018-2024 (USD Million)
TABLE 171 India CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 172 India CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 173 India CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 174 India CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 175 India CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 176 India CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 177 India CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 178 India CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 179 India CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 180 India CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 181 China CBT market size, by product, 2013-2017 (USD Million)
TABLE 182 China CBT market size, by product, 2018-2024 (USD Million)
TABLE 183 China CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 184 China CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 185 China CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 186 China CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 187 China CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 188 China CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 189 China CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 190 China CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 191 China CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 192 China CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 193 Japan CBT market size, by product, 2013-2017 (USD Million)
TABLE 194 Japan CBT market size, by product, 2018-2024 (USD Million)
TABLE 195 Japan CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 196 Japan CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 197 Japan CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 198 Japan CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 199 Japan CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 200 Japan CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 201 Japan CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 202 Japan CBT market size, by blood cell growth factors, 2018-2024 (USD Million)
TABLE 203 Japan CBT market size, by cytokines, 2013-2017 (USD Million)
TABLE 204 Japan CBT market size, by cytokines, 2018-2024 (USD Million)
TABLE 205 Latin America CBT market size, by country, 2013-2017 (USD Million)
TABLE 206 Latin America CBT market size, by country, 2018-2024 (USD Million)
TABLE 207 Latin America CBT market size, by product, 2013-2017 (USD Million)
TABLE 208 Latin America CBT market size, by product, 2018-2024 (USD Million)
TABLE 209 Latin America CBT market size, by MAB, 2013-2017 (USD Million)
TABLE 210 Latin America CBT market size, by MAB, 2018-2024 (USD Million)
TABLE 211 Latin America CBT market size, by vaccines, 2013-2017 (USD Million)
TABLE 212 Latin America CBT market size, by vaccines, 2018-2024 (USD Million)
TABLE 213 Latin America CBT market size, by cancer growth blockers, 2013-2017 (USD Million)
TABLE 214 Latin America CBT market size, by cancer growth blockers, 2018-2024 (USD Million)
TABLE 215 Latin America CBT market size, by blood cell growth factors, 2013-2017 (USD Million)
TABLE 216 Latin America CBT market size, by bl

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook